Key result
Combination therapy with abciximab and half-dose reteplase yielded higher coronary patency rates at initial angiography than abciximab alone (40% vs 18%) in patients with acute MI.
Why the study?
Does the combination of abciximab plus half-dose reteplase improve coronary patency compared to abciximab alone in patients with acute myocardial infarction undergoing facilitated PCI?
Does the combination of abciximab plus half-dose reteplase improve coronary patency compared to abciximab alone in patients with acute myocardial infarction undergoing facilitated PCI?
Absolute Event Rate: 40% vs 18%
No takes yet. Share an insight, caveat, or question.
In patients with acute myocardial infarction undergoing facilitated PCI, combining abciximab with half-dose reteplase yields higher early coronary patency rates than abciximab alone.
A. Michael Lincoff (2004) conducted an editorial in Acute myocardial infarction (n=253). Abciximab plus half-dose reteplase vs. Abciximab alone was evaluated on Coronary patency rates at the time of initial angiography. Combination therapy with abciximab and half-dose reteplase yielded higher coronary patency rates at initial angiography than abciximab alone (40% vs 18%) in patients with acute MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: